Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese-cel (resecabtagene autoleucel, formerly CABA-201) in patients with pemphigus vulgaris (PV) during the …
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra, an investigational oral therapy for adults with moderately to …
Johnson & Johnson Reports Positive Phase 2b Results for Oral Ulcerative Colitis Therapy Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients Read More
CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. announced the enrollment of the first patient in its phase 3 clinical trial evaluating NTX-001, an investigational therapy designed to improve outcomes in patients …
Neuraptive Therapeutics Enrolls First Patient in Phase 3 Trial for NTX-001 Nerve Repair Therapy Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported that their drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved highly statistically significant and clinically meaningful improvements in invasive disease-free survival (IDFS) compared to trastuzumab …
ENHERTU Shows Strong Results in Early Breast Cancer Trial Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it has completed enrollment in its Phase 2 EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and …
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported new long-term open-label (OL) data for nomlabofusp in Friedreich’s ataxia (FA), showing sustained increases in frataxin (FXN) protein and consistent …
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia Read More
PHILADELPHIA, PA — Aro Biotherapeutics announced it has completed enrollment in its Phase 1b clinical trial of ABX1100, an investigational therapy for late-onset Pompe disease (LOPD). The study is designed …
Aro Biotherapeutics Completes Enrollment in Pompe Disease Trial for ABX1100 Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More